ID
14111
Descripción
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583
Palabras clave
Versiones (1)
- 30/3/16 30/3/16 -
Titular de derechos de autor
CC BY-NC 3.0
Subido en
30 de marzo de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
VX-950HPC3006 NCT01571583 Vital Signs / Anthropometric Measurements (VS) [FRMVS_VS2]
VX-950HPC3006 NCT01571583 Vital Signs / Anthropometric Measurements (VS) [FRMVS_VS2]
Similar models
VX-950HPC3006 NCT01571583 Vital Signs / Anthropometric Measurements (VS) [FRMVS_VS2]
C0038846 (UMLS CUI [1,2])
C0038846 (UMLS CUI [1,2])
C2985739 (UMLS CUI [1,2])